



(51) International Patent Classification:

C07J 43/00 (2006.01) *A61K 31/58* (2006.01)
C07J 71/00 (2006.01) *A61P 5/32* (2006.01)

(21) International Application Number:

PCT/FI2014/050518

(22) International Filing Date:

25 June 2014 (25.06.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20135694 25 June 2013 (25.06.2013)

FI

(71) Applicant: FORENDO PHARMA LTD [FI/FI]; Itäinen
Pitkätatu 4 B, FI-20520 Turku (FI).(72) Inventors: ELORANTA, Maire; c/o Forendo Pharma
Ltd, Itäinen Pitkätatu 4 B, FI-20520 Turku (FI).
HIRVELÄ, Leena; c/o Forendo Pharma Ltd, Itäinen
Pitkätatu 4 B, FI-20520 Turku (FI). KANGAS, Lauri; c/o
Forendo Pharma Ltd, Itäinen Pitkätatu 4 B, FI-20520
Turku (FI). KOSKIMIES, Pasi; c/o Forendo Pharma Ltd,
Itäinen Pitkätatu 4 B, FI-20520 Turku (FI). LAMMIN-
TAUSTA, Risto; c/o Forendo Pharma Ltd, Itäinen
Pitkätatu 4 B, FI-20520 Turku (FI). UNKILA, Mikko; c/o
Forendo Pharma Ltd, Itäinen Pitkätatu 4 B, FI-20520
Turku (FI).(74) Agent: KOLSTER OY AB; (Iso Roobertinkatu 23), P.O.
Box 148, FI-00121 Helsinki (FI).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: THERAPEUTICALLY ACTIVE 17-NITROGEN SUBSTITUTED ESTRATRIENTHIAZOLE DERIVATIVES AS IN-
HIBITORS OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASE



(57) Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2 to R7 are as defined in the claims. The invention further relates to their use as inhibitors of 17 β -HSD and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17 β -HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.

